When AI designs a drug, who gets the credit?
When the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI platform. Insilico leads a pack of companies using AI to rapidly come up with drug ideas humans might never think…
MIT Technology Review
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from MIT Technology Review.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
MIT Technology ReviewTier B
When AI designs a drug, who gets the credit?(opens original report in a new tab)
How CurrentWire compiled this story
MIT Technology Review (www.technologyreview.com), a Tier B publisher, filed this report on . CurrentWire published this page 11 hours later, on .
Signal breakdown
CurrentWire ranked this story 39.2 of 100 in the snapshot this page was rendered from.
- Freshness
- 13.2 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 4.5 of 10
- Velocity
- 0 of 5
Strongest signal: source authority, 14 of 20. How each signal is calculated.
Filed under Technology · International · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Artificial Intelligence (31).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.